GenoMe

Dow AgroSciences | October 03, 2016

Monsanto Company (NYSE: MON) and Dow AgroSciences LLC, a wholly-owned subsidiary of The Dow Chemical Company (NYSE: DOW), announced today that the companies have reached a non-exclusive global option and licensing agreement on Dow AgroSciences’ EXZACT™ Precision Technology® Platform for research and commercial development of new crop solutions across Monsanto Company’s research portfolio....

biotech | January 12, 2017

China's intellectual property authority said it considers as withdrawn the genome editing technology patent application of researchers from Hebei University of Science and Technology (HUST) and Zhejiang University since they failed to reply to a notice on time. According to the State Intellectual Property Office, since researchers Han Chunyu and Shen Xiao did not reply, the patent application for the genome editing technology NgAgo is considered to have been withdrawn, thepaper.cn reported&n...

San Jose BioCenter | January 09, 2017

Called JLABS @ NYC, 30,000-square foot facility will hold capacity for up to 30 life science startups focused on biotech, pharmaceutical, medical device and consumer health New collaboration receives $17 million in New York State funding and will support growth of healthcare solutions in the region by providing development...

einnews | March 01, 2017

Increased R&D expenditure and growth of biotechnology and pharmaceutical industries, increasing private and public sector funding, rapid advancements in sequencing and gene editing technologies, non-labeling of gene edited products as Genetically Modified Organisms (GMOs), applications in various drug discovery processes and are some of the factors driving the genome editing global market growth. Factors such as stringent regulatory framework, ethical issues concerning editing human embryo a...